Northern Europe's greater observed incidence of this side effect is obviously one of the deciding factors of Denmark's decision. It could be a statistical anoma

Northern Europe's greater observed incidence of this side effect is obviously one of the deciding factors of Denmark's decision. It could be a statistical anomaly, but concluding is premature at this point, especially when comparing with globally-reported AstraZeneca-related blood clots. Even at half the incidence of deaths reported in Norway, which would be on the order of 1:100,000, it puts the risk of a 25-year old dying from the vaccine at ~5 times the risk of dying of a Covid infection. At one tenth incidence, it's an even bet. That seems unlikely. This seems like a pretty obvious decision to me, when looking at the Covid incidence in these countries. Given that alternative vaccines are available. I'm surprised at the level of controversy, honestly. Given the presumed science-based background for the topic. Just use one of the others.